WuXi Biologics

What WuXi Biologics does

WuXi Biologics (Cayman) Inc., incorporated in 2017 as a spin-off from WuXi AppTec and publicly listed on the Hong Kong Stock Exchange (2269.HK), is a global Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end biologics development and manufacturing services. The company serves approximately 945 integrated client projects across global biopharmaceutical and biotechnology customers, with deliberate focus on complex modalities including monoclonal antibodies, bispecifics and multispecifics, antibody-drug conjugates (ADCs), and cell therapies. Headquartered in Wuxi, China, it employs 13,000+ people across China, the United States, Ireland, Germany, and Singapore, with an emerging footprint in Qatar via an MoU with Qatar Free Zones Authority.

The integrated CRDMO platform spans discovery through commercial manufacturing, anchored by proprietary technology assets: WuXia TrueSite TI for targeted integration cell line development (enabling IND timelines as short as six months), WuXiHigh 2.0 for high-concentration subcutaneous formulations (up to 230 mg/mL with ~90% viscosity reduction), WuXiUI bioprocessing (3–6× productivity gains over traditional fed-batch), and the CD3 T-Cell Engager platform (reportedly generating $200M to date with up to $4B in potential milestones). Infrastructure comprises 24 drug substance facilities and 18 drug product facilities globally, supporting 2,350+ drug substance batches and 2,260+ drug product batches by end-2025. Quality depth is evidenced by 46 successful regulatory inspections (including FDA and EMA) with a 100% PPQ success rate, plus active GMP certifications from ANVISA, MFDS, MHRA, NMPA, and EMA, alongside ISO 13485 (drug-device combination) and ISO 20400 (sustainable procurement).

Revenue is generated through professional services fees, manufacturing charges, upfront payments, milestones, and royalties under licensing arrangements. FY2025 revenue reached RMB 21.8 billion (~USD 3.2 billion), up 16.7% YoY, with IFRS net profit of RMB 5.7 billion (+45.3%) and total backlog of US$23.7 billion at year-end 2025. Approximately 45–65% of revenue derives from U.S.-based clients, with the remaining mix spread across Greater China, Europe, and emerging markets. The go-to-market is direct enterprise sales targeting large pharma, clinical-stage biotech, and government/public health buyers (e.g., Instituto Butantan for dengue vaccine manufacturing, Fiocruz MoU in Brazil). Approximately half of new programs originate from U.S. clients; commercial-stage programs grew from 21 to 25 in 2025.

Name

WuXi Biologics

Legal name

WuXi Biologics (Cayman) Inc.

Website

https://www.wuxibiologics.com/

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

WuXi Biologics is a global CRDMO providing end-to-end biologics development and manufacturing services for biopharmaceutical and biotech clients. With 13,000+ employees and 42 manufacturing facilities globally, it serves 945 integrated client projects spanning monoclonal antibodies, bispecifics, ADCs, and cell therapies.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CRDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Cell Therapy CDMO (HLAGABAD), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biologics contract manufacturing
• Cell line development services
• Process development biologics
• ADC bispecific manufacturing
• Biosafety testing services

Headquarters

HQ city

Wuxi

HQ country

China

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Integrated R, D, and M Services: Contract research, development, and manufacturing services for biologics including monoclonal antibodies, bispecifics, ADCs, and cell therapies. Revenue generated through upfront payments, milestone payments, and manufacturing fees. Manufacturing revenue grew more than 26% with commercial programs growing from 21 to 25.
2. Research Services: Discovery and research services generating record upfront payments and potential milestone values exceeding USD 4 billion in 2025 partnerships.
3. Licensing and Milestone Payments: License agreements with upfront payments, development and regulatory milestones, sales milestones, and royalty payments. Examples include Vertex Pharmaceuticals trispecific TCE agreement.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

WuXi Biologics is an open-access CRDMO providing integrated end-to-end biologics services from discovery, cell line development, and process development through GMP drug substance and drug product manufacturing, quality control, and biosafety testing for monoclonal antibodies, bispecifics, ADCs, and cell therapies. The firm operates a global network of 24 drug substance facilities and 18 drug product facilities with proprietary platforms such as WuXia TrueSite TI, WuXiHigh 2.0, WuXiUI, PatroLab, and a CD3 T-Cell Engager platform, supporting clients from IND to commercial supply under contract service and licensing agreements.

Product overview

WuXi Biologics operates as a Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated end-to-end biologics development and manufacturing services. The company offers multiple technology platforms including WuXia TrueSite TI for cell line development, WuXiHigh 2.0 for high-concentration formulations, and PatroLab for digital twin bioprocess optimization. The CRDMO+ platform supports complex modalities including bispecific/multispecific antibodies, ADCs, and T-cell engagers across its global manufacturing network spanning China, the United States, Ireland, Germany, and Singapore.

Differentiator

Problem solved

Functional benefit

Brands

• WuXia TrueSite TI Platform: Targeted integration cell line development technology for biologics manufacturing enabling precise transgene insertion into CHO cells
• WuXiHigh 2.0
• PatroLab Digital Twin Platform
• WuXiUI Bioprocessing Platform
• WuXi CD3 T-Cell Engager Platform

Products and services

• Integrated CRDMO Services for Biologics (discovery to commercial manufacturing) Contract Research, Development and Manufacturing Organization services spanning discovery, cell line development, process development, GMP drug substance and drug product manufacturing, fill-finish, and commercialization support for monoclonal antibodies, bispecifics, ADCs, and cell therapies, for global biopharmaceutical companies.
• WuXia TrueSite TI Cell Line Development Platform Targeted integration cell line development service for precise transgene insertion into CHO cells, achieving pool titers around 6.0 g/L and lead clone productivity around 8.0 g/L, with potential to cut conventional 12-month IND timelines in half.
• WuXiHigh 2.0 High-Concentration Formulation Platform High-concentration biologic formulation service enabling subcutaneous administration through protein concentrations up to 230 mg/mL and up to 90% viscosity reduction for monoclonal antibodies and other biologics clients.
• PatroLab Digital Twin Platform Digital twin service combining real-time process monitoring with Raman-based PAT and predictive in-silico modeling to enable real-time release testing and accelerate bioprocess development for biologic manufacturing clients.
• WuXiUI Intensified Bioprocessing Platform Intensified/continuous bioprocessing manufacturing platform delivering 3 to 6 times productivity improvement over traditional fed-batch methods, available as a service offering for client biologics programs.
• WuXi CD3 T-Cell Engager (TCE) Platform CD3 T-cell engager discovery and development platform, made available to partners through license and research service agreements (e.g., Vertex trispecific TCE), generating upfront, milestone, and royalty economics.
• Suzhou Biosafety Testing Center EMA-GMP-certified biosafety testing service providing quality control testing for cell banks and commercial unprocessed bulk, supporting 1,700+ IND or BLA applications to date for clients targeting global regulatory submissions.
• MFG17 Drug Substance Manufacturing Facility GMP drug substance manufacturing facility offering 9,000 liters of total manufacturing capacity supporting 80–100 batches annually across fed-batch, perfusion, and fully automated continuous manufacturing modes for biologics clients.
• DP15 Drug Product Fill-Finish Facility Drug product fill-finish manufacturing facility equipped with advanced isolator-based aseptic filling lines capable of handling liquid and lyophilized drug product manufacturing across various vial sizes for biologics clients.
• Chengdu Microbial Commercial Manufacturing Site Microbial commercial manufacturing site spanning 95,000 square meters with a 15,000 L fermenter enabling up to 110 drug substance batches annually and vial-filling capacity exceeding 10 million vials per year for recombinant biologics and vaccine clients.
• Worcester (Massachusetts) Drug Substance Manufacturing Facility Planned large-scale biologics drug substance manufacturing facility spanning 189,500 square feet with 36,000 liters capacity, serving U.S. and global biopharmaceutical clients (completion targeted 2028).
• Singapore CRDMO Hub Drug Product Facility Modular drug product manufacturing hub in Singapore Tuas Biomedical Park spanning approximately 30,000 square meters, designed to produce ~100 million pre-filled syringes and vials per year with operations expected to commence in 2027.
• Dundalk (Ireland) Single-Use Biologics Manufacturing Facility Single-use biologics drug substance manufacturing facility in Dundalk, Ireland, providing commercial-scale production for European biopharmaceutical clients using single-use technologies.
• WuXi Vaccines (Vaccine CDMO Services) Wholly-owned vaccine subsidiary providing contract vaccine development and manufacturing services for vaccine developers and public-sector vaccine programs.

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and major.

• Viridian TherapeuticscoreTechnology or Integration · 27 May 2026Non-exclusive 5-year supply agreement for veligrotug (thyroid eye disease drug). The pact includes binding volume commitments and volume-based pricing, positioning Viridian for commercial supply upon anticipated FDA approval.
• Instituto Butantan and Fundação ButantanmajorStrategic or Co-development Partner · 29 April 2026Strategic partnership supporting scaled commercial manufacturing of the Butantan-DV dengue vaccine, with GMP certification from ANVISA enabling commercial production for Latin American market.
• FiocruzmajorStrategic or Co-development Partner · 30 March 2026MoU focused on creating technological capabilities and strengthening Brazil's health industrial base, formalized during official mission to China led by Minister of Health Alexandre Padilha.
• Earendil LabscoreStrategic or Co-development Partner · 12 March 2026Strategic collaboration combining Earendil Labs' AI-driven protein engineering with WuXi Biologics' biologics development and manufacturing expertise for bispecific/multispecific antibodies and ADCs targeting autoimmune diseases, cancer, and other diseases.
• Qatar Free Zones AuthoritymajorStrategic or Co-development Partner · 11 March 2026Strategic agreement with global biologics firms including WuXi Biologics to establish manufacturing facilities in Qatar's free zones as part of Qatar's National Manufacturing Strategy 2024-30.
• Vertex PharmaceuticalscoreStrategic or Co-development Partner · 3 February 2026License and research service agreement for a trispecific T-cell Engager targeting B-cell mediated autoimmune diseases. Vertex received exclusive global rights to develop and commercialize the preclinical-stage therapy. WuXi Biologics receives upfront payment, development and regulatory milestones, sales milestones, and royalty payments, while providing contract research and development services on next-generation TCEs.
• HanchorBiocoreStrategic or Co-development Partner · 3 February 2026Strategic collaboration for development and manufacturing of next-generation bi-/multi-functional fusion protein programs using HanchorBio's Fc-Based Designer Biologics (FBDB™) platform for immunotherapy pipeline targeting oncology and autoimmune diseases.
• Sinorda BiomedicinecoreStrategic or Co-development Partner · 29 January 2026Strategic collaboration for development and manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune diseases. Plans to file IND applications with China's NMPA and US FDA in 2026.
• Qatar Free Zones AuthoritymajorStrategic or Co-development Partner · 14 January 2026MoU to establish a regional manufacturing hub in Qatar, part of WuXi Biologics' strategic expansion to provide geographically diversified supply chain solutions.
• Y-BiologicscoreTechnology or Integration · 7 January 2026CDMO agreement for triple-target immuno-oncology pipeline including AR170 (IND planned H1 2027) and AR166 (IND planned H2 2027) under Multi-AbKine platform, covering CMC development and mass production capabilities for complex multi-antibody drugs.

Scale indicators20 records

Recent moves12 records

Expansion highlights9 records

Direct peers

• Samsung Biologics: Samsung Biologics is the world's largest contract biologics manufacturer by capacity, offering mammalian cell culture and drug substance services to global biopharma. Direct competitor with overlapping modalities (mAbs, bispecifics), targeting the same enterprise biopharma clients with similar end-to-end service models.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's BioXcellence is a major mammalian-cell biologics CDMO serving global biopharma with commercial-scale manufacturing. Competitor in mammalian biologics CDMO space with overlapping customer base of large pharma clients seeking commercial-stage capacity.
• Celltrion: Celltrion operates a major biologics manufacturing business focused on biosimilars and biologics CDMO services from its Korean facilities. Competitor in the Asian biologics CDMO landscape, providing mammalian cell culture services to global clients seeking Asia-based capacity.
• AGC Biologics: AGC Biologics (formerly CMC Biologics) is a global CDMO specializing in mammalian and microbial biologics development and manufacturing. Comparable in offering end-to-end services from cell line development through commercial manufacturing to mid-sized and large biopharma customers.
• Lonza Group: Lonza is a Swiss-based global CDMO leader with the largest biologics capacity footprint including mammalian and microbial services. Comparable in offering end-to-end biologics development and manufacturing to global pharma and biotech customers, including complex modalities.
• WuXi STA: WuXi STA is the sister small-molecule CDMO within the WuXi AppTec ecosystem, providing chemistry, manufacturing, and controls services. Comparable as a CRDMO in the broader WuXi group with overlapping services, sales channels, and biopharma client relationships focused on different modalities.

Broad incumbents

• Thermo Fisher Scientific (Patheon/CDMO): Thermo Fisher's pharma services segment operates a global biologics CDMO through its Patheon network with viral vector and biologics manufacturing. Comparable as a broad incumbent offering multiple CDMO services including biologics development and manufacturing alongside adjacent pharma services.
• Catalent (Novo Holdings): Catalent is a major global CDMO (now owned by Novo Holdings) with broad biologics and cell therapy capabilities including sterile fill-finish, gene therapy, and biomanufacturing. Overlap with WuXi's biologics drug product and cell therapy services, though Catalent's broader portfolio spans small molecules and consumer health.

Others

• WuXi XDC: WuXi XDC is the Hong Kong-listed ADC-focused CRDCO spun out as a joint venture between WuXi Biologics and WuXi STA. Sister company and ecosystem participant focused on bioconjugate drug development, with strong technology synergy with WuXi Biologics' antibody capabilities.

Emerging players

• Samsung Bioepis: Samsung Bioepis is a biosimilars-focused biologics developer and manufacturer within the Samsung group. Not a direct CDMO competitor but operates adjacent manufacturing capabilities that interact with Samsung Biologics' CDMO arm, making it an ecosystem participant in Korean biologics production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wuxibiologics

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi Biologics